Skip to content
Open in App
Insmed logo

Insmed

web2

Insmed Incorporated develops and commercializes therapies for patients with serious and rare di...

Symbol · 1INSM
Company profile

About

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Positive Phase 3b ENCORE topline results for ARIKAYCE

KEY STEP

On March 23, 2026, Insmed announced positive topline results from the Phase 3b ENCORE study of ARIKAYCE in patients with a new occurrence of MAC lung disease who had not received antibiotics. The study met its primary respiratory symptom endpoint and all multiplicity controlled culture conversion endpoints.

Roadmap reference

Brensocatib CEDAR study fails and HS program is discontinued

KEY STEP

On April 7, 2026, Insmed announced that the Phase 2b CEDAR study of brensocatib in moderate to severe hidradenitis suppurativa did not meet its primary or secondary efficacy endpoints in either tested dose. The company said it would discontinue development of brensocatib in hidradenitis suppurativa. No new safety signals were identified.

Roadmap reference

BRINSUPRI approved in Japan for non cystic fibrosis bronchiectasis

KEY STEP

On August 24, 2026, Japan’s Ministry of Health, Labour and Welfare approved BRINSUPRI 25 mg for the treatment of non cystic fibrosis bronchiectasis in adults and pediatric patients 12 years and older. The approval made BRINSUPRI an approved therapy in the United States, Europe and Japan.

Roadmap reference
People

Company team

EM

Elizabeth McKee Anderson

Independent Director

Company leadership profile.

WH

William H. Lewis

President, CEO & Chairman

Company leadership profile.

DR

David R. Brennan

Lead Independent Director

Company leadership profile.

CA

Carol A. Schafer

Independent Director

Company leadership profile.

MS

Melvin Sharoky

Independent Director

Company leadership profile.

LL

Leo Lee

Independent Director

Company leadership profile.

CD

Clarissa Desjardins

Independent Director

Company leadership profile.

Expert coverage

1 expert evaluated Insmed.

Orbitrum research

Experts evaluating Insmed

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment